ST2 in Stable and Unstable Ischemic Heart Diseases by Richards, Am et al.
aChrist
Zealand; b
Centre, Sin
lational M
drea Hosp
Konventho
Publica
Diagnostic
Statem
section at
*Addre
Research I
NUHS T
Singapore
E-mail
0002-9149
http://dx.doST2 in Stable and Unstable Ischemic Heart Diseases
A. Mark Richards, MDa,b,*, Salvatore Di Somma, MDc, and Thomas Mueller, MDdCirculating suppression of tumorigenicity 2 (ST2) predicts cardiovascular outcomeschurch Hea
Cardiovasc
gapore; cD
edicine, Un
ital, Rome
spital Barm
tion of this
s, San Dieg
ent of auth
end of this
ss for repri
nstitute, Na
ower Blo
119228.
address: m
/15/$ - see
i.org/10.10and mortality in ischemic heart disease (IHD). ST2 does not correlate with traditional
risk indicators as closely as N-terminal proebrain natriuretic peptide (NT-proBNP)
and is only weakly correlated with other biomarkers, indicating distinct pathways for
stimulus and release. Although of little diagnostic utility in IHD, ST2 does offer
prognostic information. In ST elevation myocardial infarction, ST2 levels increase to
peak above the normal reference range (within 6 to 18 hours of symptom onset) in
about half of patients. Levels in the upper quartile observed in IHD independently
predict cardiovascular death and heart failure with an approximate doubling of risk.
Similar but weaker associations have been reported in noneST elevation myocardial
infarction, in which ST2 predicts short-term (30-day) and long-term (>1-year) death
and heart failure independent of clinical indicators, but these relations are lost if
Global Registry of Acute Coronary Events (GRACE) score and NT-proBNP are
added to multivariate models. Early postinfarction levels of ST2 (i.e., <24 hours after
admission) have the greatest prognostic utility. Early postinfarction ST2 levels and
change over 24 weeks are related to infarct extent and remodeling to a similar extent
as NT-proBNP and aldosterone, and ST2 may have a significant pathophysiological
role in these postinfarction processes. In long-term follow-up of stable IHD, ST2 is
predictive of all-cause and cardiovascular mortality independent of accepted clinical
indicators and other biomarkers, including NT-proBNP, high-sensitivity C-reactive
protein, interleukin-6, high-sensitivitiy cardiac troponin T, and galectin-3. In
conclusion, ST2 in combination with NT-proBNP consistently improves risk strati-
fication compared with either marker alone.  2015 Elsevier Inc. All rights reserved.
(Am J Cardiol 2015;115[suppl]:48Be58B)The suppression of tumorigenicity 2 (ST2) protein was
identified >20 years ago but remained an orphan receptor
until confirmation, in 2005, of interleukin-33 (IL-33) as its
endogenous ligand.1 In vitro expression of ST2 is upregu-
lated with cardiomyocyte stretch.2 In vivo cardiac loading is
associated with an increase in circulating levels of ST2. ST2
is present in circulating and membrane-bound forms. In
experimental myocardial infarction (MI), IL-33 prevents
apoptosis and improves cardiac function and survival.3 It
has been suggested that circulating “soluble ST2” may act as
a “decoy” for IL-33 and in this way reduce access of the
interleukin to cardiac membraneebound receptors, thusrt Institute, University of Otago, Christchurch, New
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This review summarizes findings with respect to plasma
ST2 concentrations and their relations to clinical outcomes
across the spectrum of ischemic heart disease (IHD) pre-
sentations ranging from populations with undifferentiated
chest pain through acute coronary syndromes (ACS) to
chronic stable IHD (Table 1).ST2 in Undifferentiated Chest Pain
Two reports have addressed the diagnostic and prognostic
performance of plasma ST2 concentrations in patients pre-
senting to emergency departments with chest pain.4,5
Brown et al4 enrolled 348 patients, aged 25 years, pre-
senting to emergency departments with chest pain triggering
the acquisition of an electrocardiogram. Blood for ST2
(measured using a research useeonly assay) was obtained at
presentation, and levels were subsequently assessed for re-
lations to 30-day event rates for acute MI (AMI), ACS, and
adverse cardiac events (defined as all-cause mortality, AMI,
or revascularization [angioplasty, stent placement, or coro-
nary artery bypass surgery]). Event rates were low at 4.9%
(n¼ 17) for AMI, 11.2% (n¼ 39) for ACS, and 6.6% (n¼ 23)
for the composite end point. Areas under the receiver-
operating characteristic curves (AUCs) for the detection ofwww.AJConline.org
Richards et al/ST2 in Ischemic Heart Disease 49BAMI, ACS, and the composite end point were low at 0.636,
0.630, and 0.579, respectively. The investigators concluded
that ST2 was not useful in the evaluation of emergency
department patients with suspected but not proved ACS.
Aldous et al5 revisited the diagnostic and prognostic
utility of ST2 in patients with chest pain in a larger group
with longer follow-up and found associations between ST2
and later all-cause mortality and incident heart failure (HF).
Nine hundred ninety-five patients reporting ischemic-type
pain (including acute chest, gastric, neck, jaw, or arm pain
or discomfort or pressure without apparent noncardiac
source) were recruited. Blood samples were acquired at
0 and 2 hours after presentation for the measurement of ST2,
brain natriuretic peptide (BNP), troponin I (TnI), creatine
kinase-MB fraction, and myoglobin. ST2 was weakly
correlated with all 4 of the other markers (R ¼ 0.06 to 0.30,
p ¼ 0.044 to 0.001, with the strongest correlation with
BNP).
The diagnostic performance for the index admission and
prognostic performance for events after discharge and up
18 months were assessed for each marker. End points
included the composite of all-cause mortality and HF and
the individual end points: all-cause mortality, AMI, revas-
cularization, arrhythmia, and stroke. The cut points chosen
for each marker were the upper-limit normal values as
indicated by the test kit manufacturers. For ST2 this was the
95th percentile of the Critical Diagnostics Presage ST2
assay, 34.3 ng/ml (limit of detection 1.61 ng/ml, coefficient
of variation 10% at 16.9 ng/ml, and normal range 1.75 to
34.3 ng/ml). Patients with ST2 >34.3 ng/ml (221 of 995)
were more likely to be older; to be female; to have histories
of HF, lung disease, diabetes, hypertension, and dyslipide-
mia; to have lower left ventricular (LV) ejection fractions
(LVEFs); to have more frequent regional wall abnormalities;
and to have higher plasma creatinine. Events during the
index admission included 35 primary end points, 1 death, 34
episodes of HF, and 236 AMIs. ST2 levels were signifi-
cantly higher in patients with compared with those without
these end points.
Relative to the diagnosis of AMI, ST2 clearly under-
performed troponin (sensitivity 31.2%, specificity 80.5%
compared with TnI at 94.5% and 95.7%, respectively), while
for the diagnosis of acuteHF,ST2 lacked the sensitivityofBNP
(73.5 vs 88.2%) but had higher specificity (79.6 vs 66.2%).
In contrast to performance for diagnosis, the prognostic
performance of ST2 for postdischarge events up to 18-month
follow-up was notable. Events from discharge till 18-month
included 110 primary (i.e., all-cause death and HF) events
(11.1%), 73 deaths (7.3%), 52 HF events (5.2%), 86 AMIs
(8.6%), 57 revascularizations (5.7%), 49 arrhythmias (4.9%),
and 19 strokes (1.9%). Survival (Kaplan-Meier) curve ana-
lyses indicated a steep increase in risk in those with admission
and/or 2-hour ST2 levels above the third quartile (33.4 ng/ml),
a level close to the 95th percentile (34.3 ng/ml) used to define
the upper limit of normal. Eighteen-month event rates for the
primary end point were 4.9%, 7.6%, 7.2%, and 24.5% in ST2quartiles 1, 2, 3, and 4, respectively. Similar results were
found for each of death, AMI, HF, arrhythmia, and stroke.
Prognostic associations between ST2 and important adverse
events remained evident after multivariate analyses that
adjusted for age; gender; ethnicity; history of IHD, HF, lung
disease, revascularization, stroke, hypertension, and dyslipi-
demia; smoking status; diabetes; bodymass index; the LVEF;
regional wall abnormality score; and plasma creatinine. ST2,
age, BNP, TnI, myoglobin, the LVEF, and previous IHDwere
all independently prognostic for the primary outcome.
Elevated ST2 predicted the primary outcome (hazard
ratio [HR] 1.9; 95% confidence interval [CI] 1.2 to 3.2),
which was inferior to BNP (HR 2.8; 95% CI 1.4 to 5.7),
equivalent to myoglobin levels, and superior to TnI and
creatine kinase-MB, although for all comparisons, overlap
of 95% CIs existed. In those with initial diagnoses of AMI,
ST2 predicted later primary outcome (HR 2.7; 95% CI 1.2
to 5.7) ST2 also predicted later HF (HR 2.2; 95% CI 1.0 to
4.7) in the population overall. Notably, ST2 was not an
independent predictor of later AMI or revascularization.
ST2 combined with BNP improved risk stratification
beyond that achieved with either marker alone. Rates for the
primary end point over follow-up for those with both
markers elevated, BNP alone elevated, ST2 alone elevated,
or neither marker raised were 36.8%, 19.4%, 6.8%, and
2.2%, respectively.
This study was the first to assess the relation of early ST2
levels to later mortality and HF events over prolonged
follow-up in a large undifferentiated chest pain population
and to compare this prognostic performance with that of
other markers. The association of ST2 with death and HF
was retained after comprehensive adjustment for other pre-
dictors. ST2 and BNP combine to provide better risk strat-
ification than obtained with either alone.ST2 in ST Elevation Myocardial Infarction
Two reports on data derived from 3 randomized clinical
trials of experimental therapy in ST elevation MI (STEMI)
provide data on the predictive power of plasma ST2 for
adverse events up to 30 days after MI, and a further article
reported on prognostic performance out to a median follow-
up duration of 20 months.6e8 ST2 was measured in >2,000
patients participating in Thrombolysis In Myocardial
Infarction (TIMI) 14, Enoxaparin and Tenecteplase With or
Without Glycoprotein IIb/IIIa Inhibitor as Reperfusion
Strategy in ST Elevation MI (ENTIRE)eTIMI 23 and
Clopidogrel as Adjunctive Reperfusion Therapy (CLAR-
ITY)eTIMI 28 trials.6,7
Shimpo et al6 measured ST2 in 810 patients with STEMI
(362 from TIMI 14 and 448 from ENTIREeTIMI 23).
Patients recruited to these trials had episodes of ischemic
discomfort for 30 minutes within 6 hours (ENTIREeTIMI
23) or 12 hours (TIMI 14) and exhibited 0.1-mV
ST-segment elevation in 2 contiguous electrocardiographic
Table 1
Characterization of outcome studies on stable and unstable ischemic heart disease with sST2 as the target parameter
Article Study population,
disease group
Setting Primary endpoint Follow-up Number of patients
who reached
endpoint
sST2 assay*
Brown AM et al
20074
n¼348
chest pain
emergency department
patients
composite of all-cause
mortality, acute MI, or re-
vascularization
exactly 30 days for each
study participant
n¼23 (7%) MBL assay (commercially
available ready-to-use
assay)
Aldous SJ et al
20125
n¼995
chest pain
emergency department
patients, post-hoc
analysis of a
prospectively
conducted multicenter
study
composite of all-cause
mortality and heart failure
exactly 1.5 years for each
study participant
n¼110 (11%) Presage assay
(commercially available
ready-to-use assay)
Shimpo M et al
20046
n¼810
STEMI
hospitalized patients,
TIMI 14 and
ENTIRE-TIMI
23 trial
participants
all-cause mortality exactly 30 days for each
study participant
n¼28 (3%) MBL assay (commercially
available ready-to-use
assay)
Sabatine MS
et al 20087
n¼1239
STEMI
hospitalized patients,
CLARITY-TIMI 28
substudy
composite of cardiovascular
death and heart failure
exactly 30 days for each
study participant
n¼87 (7%) MBL assay
(commercially
available ready-to-use
assay)
Dhillon OS et al
20138
n¼667
STEMI
hospitalized patients all-cause mortality exactly 1.0 year for each
study participant
n¼58 (9%) in-house assay
(constructed by the
respective
researchers)
Eggers KM et al
201010
n¼403
NSTEMI
hospitalized patients,
GUSTO IV substudy
on inflammatory
markers
all-cause mortality exactly 1.0 year for each
study participant
n¼22 (6%) Presage assay
(commercially
available ready-to-use
assay)
Dhillon OS et al
201111
n¼577
NSTEMI
hospitalized patients composite of all-cause
mortality, heart
failure hospitalization, and
re-infarction
mean of approx. 1.5 years n¼156 (27%) in-house assay (constructed
by the respective
researchers)
Kohli P et al
201212
n¼4426
NSTEMI
hospitalized patients,
substudy of the
MERLIN-TIMI 36
trial
composite of cardiovascular
mortality and new or
worsening heart failure
mean of approx. 1.0 year not provided Presage assay
(commercially available
ready-to-use assay)
Demyanets S
et al 201413
n¼373
STEMI,
NSTEMI,
and stable
angina
hospitalized patients all-cause mortality mean of approx. 3.5 years n¼37 (10%) R&D assay (commercially
available ready-to-use
assay)
Dieplinger B
et al 201415
n¼1345
stable coronary
artery disease
hospitalized patients,
substudy of the
LURIC study
all-cause mortality median of approx. 9.8 years n¼477 (36%) Presage assay
(commercially
available ready-to-use
assay)
Weir RA et al
201016
n¼100
acute MI
hospitalized patients left ventricular functional
recovery after acute MI
exactly 24 weeks for each
study participant
not applicable R&D assay
(commercially
available ready-to-use
assay)
BNP, B-type natriuretic peptide; CI, confidence interval; CRP, C-reactive protein; cTnI, cardiac troponin I; cTnT, cardiac troponin T; GRACE score, Global Registry of Acute
Coronary Events risk score; HR, hazard ratio; IL-6, interleukin-6; IL-33, interleukin-33; LVEF, left ventricular ejection fraction; MI, myocardial infarction; n.a., not applicable;
NSTEMI, non-ST-segment elevation acute coronary syndrome, NT-proBNP, N-terminal pro B-type natriuretic peptide; STEMI, ST-segment elevation myocardial infarction.
*Results obtained with different sST2 assays are not comparable; the assays are not standardized. One should be aware with which method the results were
produced. Commercially available assays: Presage assay (Presage ST2 kit, Critical Diagnostics, San Diego, CA, USA), the MBL ST2 assay (Human ST2
ELISA kit, Medical&Biological Laboratories, Woburn, MA, USA), and the R&D ST2 assay (ST2/IL-1 R4 DuoSet ELISA or Quantikine ELISA, R&D
Systems, Minneapolis, MN, USA).
50B The American Journal of Cardiology (www.AJConline.org) Vol 115 (7S) April 2, 2015leads. Blood for ST2 measurements was taken at presenta-
tion. Using an older generation research useeonly ST2
assay (Medical and Biological Laboratories Co., Ltd.) the
authors found levels higher (0.379 vs 0.233 ng/ml,
p <0.001) in those who died or developed HF over 30 days
after STEMI. Ascending quartiles of plasma ST2 signifi-
cantly corresponded to increasing time from symptom onset,higher heart rates, higher cardiac TnI, higher BNP, higher
C-reactive protein (CRP), higher creatinine, and increasing
likelihood of an anterior location of the MI. Notably most of
the elevation in these covariates occurred between the third
and fourth quartiles of plasma ST2. In this STEMI popu-
lation, ST2 was correlated weakly with TnI (r ¼ 0.26,
p <0.0001) but not with BNP. Over 30 days, events
Utilization of sST2 as
predictor variable
HR (95% CI) in
univariate
Cox-regression
HR (95% CI) in
multivariate
Cox-regression
Other independent variables in
multivariate
Cox-regression
Cut-point reported for
sST2*
Additional information
continuous not applied not applied not applied no cut-point provided area under the curve for prediction
of outcome, 0.58 (95% CI, 0.48-
0.68)
dichotomous, >34 ng/
mL
not provided 1.9 (1.2-3.2) a variety of clinical variables and
several biomarkers including BNP
and cTnI
34 ng/mL, cut-point by
95th percentile
sST2, cTnI and BNP provided
independent prognostic
information
incremental, per 1 ng/
mL rise
not provided 1.8 (1.0-3.1) clinical variables only (age, heart rate,
systolic blood pressure, location of
MI, Killip class, and time from
onset of chest pain)
0.235 ng/mL, cut-point
by median
sST2 lost its independent prognostic
value when BNP and cTnI were
entered into multivariate analysis
incremental, log10-
transformed
concentrations per 1
unit
2.4 (1.7-3.5) (cave: this is
an odds ratio because
logistic regression was
applied)
1.9 (1.3-3.0) (cave: this is
an odds ratio because
logistic regression was
applied)
clinical variables only (including
infarct location, Killip class, time to
initiation of fibrinolytic therapy,
and type of lytic)
0.080 ng/mL, cut-point
by median
sST2 and NT-proBNP provided
independent and additive
prognostic information
incremental, log10-
transformed
concentrations per 1
unit
9.1 (5.2-16.0) 2.6 (1.2-5.4) a variety of clinical variables including
GRACE score and several
biomarkers including NT-proBNP
(but not cTnI or cTnT)
0.862 ng/mL, cut-point
set arbitrarily
for 30-day mortality
sST2 and IL-33 were
simultaneously evaluated as
outcome predictors
incremental, loge-
transformed
concentrations per 1
standard deviation
not provided 2.3 (1.1-4.6) (cave: this is
an odds ratio because
logistic regression was
applied)
age, heart failure, diabetes mellitus,
previous MI or stroke, but no
biomarkers (such as NT-proBNP,
cTnT or CPR)
no cut-point provided serial measurement of sST2: sST2
concentrations decreased in time
course from baseline to 72 hours
thereafter
incremental, log10-
transformed
concentrations per 1
unit
3.6 (2.3-5.6) 2.0 (1.2-3.3) a variety of clinical variables and
several biomarkers including cTnI
no cut-point provided sST2 lost its independent prognostic
valuewhenGRACEscore andNT-
proBNP were entered into
multivariate analysis
incremental, log10-
transformed
concentrations per 1
unit
1.6 (1.4-1.7) 1.3 (1.1-1.4) a variety of clinical variables and
several biomarkers including BNP
and cTnI
35 ng/mL, cut-point by
highest quartile
sST2, cTnI and BNP provided
independent and additive
prognostic information
dichotomous, >0.538
ng/mL
2.1 (1.1-4.2) 2.2 (1.1-4.4) age, gender, hyper-lipidemia, hyper-
tension, smoking, creatinine but no
biomarkers (such as NT-proBNP,
cTnT or CPR)
0.538 ng/mL, cut-point
by highest quintile
sST2 and IL-33 were
simultaneously evaluated as
outcome predictors
incremental, log10-
transformed
concentrations per 1
standard deviation
1.5 (1.3-1.6) 1.2 (1.0-1.3) a variety of clinical variables and
several biomarkers including cTnT,
NT-proBNP, CRP, IL-6, and
galectin-3
25 ng/mL, cut-point by
highest quartile
sST2, cTnT and NT-proBNP
provided independent and
additive prognostic information
sST2 was correlated
with baseline and 24-
week measurements
of LV function
not applied not applied not applied no cut-point provided baseline sST2 was associated with
baseline and 24-week LVEF and
with baseline and 24-week infarct
volume index
Table 1
(continued)
Richards et al/ST2 in Ischemic Heart Disease 51Bincluded 28 deaths, 29 recurrent MIs, 21 HF events, and 47
death and HF composite events. ST2 levels were higher in
subsequent decedents than in survivors and also in those
incurring HF but not in those with recurrent MI. This pattern
reinforces the repeated finding that ST2 predicts death and
HF but not recurrent ischemic events. Despite these rela-
tively small numbers of events, risk for inpatient deathincreased with quartile of ST2 (0.98%, 1.5%, 3.0%, and
6.4% in quartiles 1, 2, 3, and 4, respectively; p ¼ 0.0008),
whereas corresponding percentages for in-hospital recurrent
MI (4.4%, 3.5%, 0.5%, and 1.5%, respectively) showed no
pattern of association with increasing ST2. Thirty-day event
rates also revealed the key ST2-associated end points to be
death and HF. Notably, those with inframedian levels of
52B The American Journal of Cardiology (www.AJConline.org) Vol 115 (7S) April 2, 2015ST2 on admission incurred no further death or HF in the
interval between discharge and 30-day follow-up. Again,
there was no association with increased risk for recurrent MI
at 30 days, with an almost inverse trend between quartile of
ST2 and risk for new MI (5.4%, 4.5%, 2.5%, and 2.0% in
ST2 quartiles 1, 2, 3, and 4, respectively).
In multivariate analysis ST2 remained predictive of
mortality at 30 days, after controlling for age, heart rate,
blood pressure, location of infarction, Killip class, and time
from symptom onset (HR per 1 ng/ml increase 1.77; 95% CI
1.01 to 3.12, p ¼ 0.047), but the independent association
was lost once BNP and TnI were added to the model (this
was possible only for n ¼ 448 in the ENTIREeTIMI 23
subpopulation). In the TIMI 14 subcohort, additional sam-
ples were taken at later time points, and ST2 at 12 hours
from presentation remained independently predictive of
mortality after adjustment for age, heart rate, blood pressure,
location of MI, Killip class, and time from symptom onset (p
<0.01). The investigators concluded that ST2 is associated
with mortality after STEMI independent of established
clinical indicators. They did not provide any assessment of
the risk stratification potentially offered by marker combi-
nations such as ST2 coupled with either TnI or BNP.
These findings were reinforced and extended by data from
the CLARITYeTIMI 28 trial in STEMI, which also provided
a compelling analysis of the complementarity of ST2 and the
established marker N-terminal pro-BNP (NT-proBNP).7 ST2
was measured on recruitment to the trial in 1,239 patients.
Ascending quartiles of plasma ST2 were associated with
diabetes, creatinine clearance (although the difference in
estimated glomerular filtration rate (eGFR) between ST2
quartiles 1 to 4was<6ml/min) but not related to other clinical
characteristics often considered to associate with chronic LV
wall stress, including age, hypertension, previous MI, or
previousHF. The correlation withNT-proBNPwasweak (r¼
0.14, p <0.001). NT-proBNP was correlated with age,
gender, hypertension, previous MI, previous HF, and lower
creatinine clearance (quartile 1 to quartile 4 ST2 interquartile
difference in eGFR about 16 ml/min). This striking non-
parallelism of the relations of the 2 markers with common
covariates supports the concept of different primary drivers
for their production and secretion.
The temporal patterns of change in plasma ST2 and
NT-proBNP in the post-MI period also differ. Repeat sam-
pling in most patients was undertaken at angiography a
mean of about 4 days after MI. ST2 decreased modestly an
average of 0.009 ng/ml, while mean NT-proBNP increased
nearly sixfold by an average of 386 pg/ml (p <0.001 for the
2 changes from baseline). Notably, plasma ST2 differed
between patients with and without angiographic TIMI flow
grade 0 and between those with and without TIMI
myocardial perfusion grade 0 (both adverse appearances
were associated with about threefold higher ST2 levels) than
was the case for NT-proBNP (about 40% differences),
whereas the natriuretic peptide marker was clearly more
closely associated with LVEF than ST2 (r ¼ 0.45 vsr ¼ 0.17). These findings suggest plasma ST2 reflects the
quantum of injured tissue and associated necrosis and
inflammatory events, whereas the primary driver for
NT-proBNP remains cardiac mechanical stress.
For ST2 and NT-proBNP, the mean plasma concentra-
tions observed in those later incurring cardiovascular (CV)
death or HF were four- to fivefold those in patients spared
these outcomes. In patients later experiencing strokes,
marker levels were two- to four-fold those in patients spared
stroke. In contrast, ST2 levels were almost identical (0.074
vs 0.079 ng/ml) in those with and without later recurrent MI.
Although NT-proBNP levels did differ for this end point
(108 vs 70 pg/ml, p ¼ 0.0013), it was to a far lesser degree
than for death or HF. Thirty-day CV death rates by quartile
of ST2 were 2.5%, 3.2%, 3.2%, and 9% in quartiles 1, 2, 3,
and 4, respectively, with corresponding percentages of
1.4%, 1.0%, 5.1%, and 10.5% for successive quartiles of
NT-proBNP. Similar patterns were observed for incident
HF. The most pronounced increase in risk occurred from the
third to the fourth quartile of ST2 values, whereas the
increasing risk associated with increasing NT-proBNP was
more smoothly graded across successive quartiles. Notably,
ST2 levels at baseline were superior to levels 4 days later
(i.e., at angiography) for the prediction of death or HF,
whereas the opposite was true of NT-proBNP. If corrobo-
rated, this observation will inform optimal peri-infarct
timing of sampling, which, for prognostic applications,
may differ for these 2 markers.
In multivariate analysis with adjustment for age, gender,
hypertension, diabetes, previous MI, previous HF, creati-
nine clearance, infarct location, Killip class, time from
symptom onset to lytic therapy, and peak creatine kinase, a
1-SD elevation in log-transformed ST2 was associated
with a 1.94-fold (95% CI 1.25-fold to 3.03-fold) increase
in risk for CV death or HF over 30 days (p ¼ 0.003). The
analogous result for NT-proBNP was 1.46-fold (95%
CI 1.22-fold to 1.76-fold, p <0.001). In a multimarker
model including ST2 and NT-proBNP plus all the tradi-
tional predictors, the 2 markers remained independent
predictors of CV death or HF, with odds ratios per 1-SD
elevation in log levels of 1.88 (95% CI 1.17 to 3.03,
p ¼ 0.009) and 1.41 (95% CI 1.17 to 1.69, p <0.001) for
ST2 and NT-proBNP, respectively. Figure 1 illustrates
combined risk stratification using TIMI risk score together
with ST2 and NT-proBNP.
Risk for CV death or HF at 30 days increased from about
0.6% when neither marker was elevated above the median
value for the group and the TIMI risk score was 0 or 1 to
about 26% when the 2 markers were above the median
values and the TIMI risk score was 4 (Figure 1). When the
2 markers were included in the model, the c-statistic for
prediction of death or HF increased from 0.82 to 0.86. In
summary, this study demonstrated ST2 to be a strong
predictor of CV death within 30 days after STEMI inde-
pendent of traditional risk factors and complementary to
NT-proBNP.
Figure 1. Combined risk stratification with the TIMI risk score for STEMI
and NT-proBNP and ST2. Rate of CV death or HF in patients was cate-
gorized into 9 groups on the basis of the TIMI risk score for STEMI and
biomarker status; the latter was categorized as neither ST2 and NT-proBNP
higher than the median, 1 of the 2 higher than the median, or both higher
than the median. The numbers of patients with events and patients in each
group are as follows (from left to right and from back to front): 36 of 141,
10 of 121, 5 of 59, 16 of 125, 9 of 226, 3 of 181, 4 of 38, 3 of 109, and 1 of
167.7
Richards et al/ST2 in Ischemic Heart Disease 53BDhillon et al8 measured ST2 and its endogenous ligand,
IL-33, in a study of patients with STEMI that extended the
window of observation beyond 30 days out to a median
follow-up duration of about 20 months. ST2 and IL-33 were
measured in samples acquired 3 to 5 days after admission in
677 patients with STEMI. Median follow-up duration was
587 days (interquartile range [IQR] 134 to 2,818), during
which 101 patients (15%) died.
ST2 was correlated with NT-proBNP (r ¼ 0.32), Global
Registry of Acute Coronary Events (GRACE) risk score
(r ¼ 0.22), age (r ¼ 0.20), and peak creatinine phosphoki-
nase (r ¼ 0.16) and negatively with eGFR (r ¼ 0.22), all
significant at p <0.001. As in previous studies, supramedian
levels of ST2 (>0.677 ng/ml) were associated with greater
age, a higher rate of diabetes, lower eGFR, a lower ejection
faction, a higher GRACE score, and higher NT-proBNP
level. They also tracked with lower rates of prescription of
indicated drugs (angiotensin-converting enzyme inhibitors
or angiotensin II receptor blockers, b blockers, aspirin, and
statins) at discharge.
Importantly, supramedian ST2 was associated with
threefold greater rates of death and HF. Levels in subsequent
decedents were significantly higher than in survivors (median
1.125 ng/ml [range 0.123 to 15.781] vs 0.630 ng/ml [range
0.590 to 11.729], p <0.001), as were IL-33 levels (median
75 pg/ml [range 5.4 to 17,983] vs 5.4 pg/ml [range 5.4 to
16,466], p ¼ 0.006). For multivariate analysis, a Cox
regression model was constructed including age, gender,
history of angina or AMI, hypertension, diabetes, Killip class,
eGFR, peak creatine kinase level, and treatment with throm-
bolysis, b blockers, statins, angiotensin-converting enzyme
inhibitors, or angiotensin II receptor blockers. ST2 was
associated with increased risk for death within 30 days (HR
9.34, p <0.001) and at 1 year (HR 3.15, p ¼ 0.001). Thepredictive power of ST2 was retained after further adjustment
for GRACE risk score as calculated on admission9 and
NT-proBNP. The c-statistic for prediction of death by 30 days
improved from 0.82 to 0.84 for any 1 of the 3 predictors alone
to 0.90 (p ¼ 0.01) when ST2, GRACE risk score, and
NT-proBNP were combined. IL-33 >5.4 pg/ml was inde-
pendently predictive of 30-day and 1-year mortality but did
not add prognostic information over that provided byGRACE
risk score or NT-proBNP. Those readmitted with HF had
higher ST2 (1.081 ng/ml, p<0.001) comparedwith the event-
free group. On univariate analysis, ST2 was associated with
HF readmission at 30 days and 1 year, but this did not retain
statistical significance after multivariate adjustment. This
discrepancy with earlier studies is not readily explained, but it
may reflect the timing of sampling. In Sabatine et al,7
admission values of ST2 were notably better at prediction
of CV death or HF than were levels at 4 days after admission.
Dhillon et al8 collected samples at 3 to 5 days and may
therefore have lost some of the prognostic power of plasma
ST2 for this end point. For those who experienced reinfarc-
tion, ST2 levels were similar to those in the event-free group
(0.649 ng/ml, p ¼ 0.89). Consistent with earlier reports, on
univariate analysis and after multivariate adjustment, higher
ST2 predicted lower recurrent MI (HR 0.13, p ¼ 0.004).
Notably, IL-33 levels were lower than the limit of
detection in half of patients, possibly obscuring the true
relation between IL-33 and outcomes. Development of more
sensitive assays may allow this question to be revisited at a
later time.
This report consolidates consistent findings in STEMI
with respect to the prognostic utility of ST2 in the early (30-
day) post-MI period and also indicates that the prognostic
signal (for death) offered by ST2 levels extends beyond
30 days to 1 year. ST2 adds to information from tradi-
tional risk indicators (including those integrated in the
admission GRACE score) and from NT-proBNP. The in-
verse relation with risk for recurrent MI has now been
observed in all 3 reports of STEMI series, although its
mechanism remains obscure. It is possible that patients with
high peri-infarct ST2 have incurred more “complete” in-
farcts, whereas lower ST2 levels in STEMI may signify
“unfinished business,” with high-risk coronary plaque and
anatomy remaining in situ to pose a continued risk for
reinfarction.ST2 in NoneST Elevation Acute Coronary Syndromes
The performance of ST2 in non-STEMI (NSTEMI) and
noneST elevation ACS overall has been explored in at least
4 reports since 2010.10e13
Eggers et al10 studied serial ST2 levels measured using
the Critical Diagnostics Presage ST2 assay in 403 of 7,800
patients recruited into the Global Use of Strategies to Open
Occluded Arteries (GUSTO) IV study. Patients were
eligible for inclusion in GUSTO IV (a randomized trial of
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neutral results) if they had ischemic symptoms lasting
5 minutes <24 hours before admission together with
either a positive cardiac troponin test result (above the upper
limit of normal for the local assay) or 0.5-mm ST-segment
depression. Blood samples were acquired at randomization
and at 24, 48, and 72 hours after randomization. Other
biomarkers, measured at randomization only, included
troponin T, NT-proBNP, CRP, and interleukin-6 (IL-6).
Peak ST2 levels were observed at 6 to 17 hours after
symptom onset, consistent with data previously reported in
STEMI patients.6 Levels subsequently decreased to a stable
level of about 20 ng/ml by 24 to 42 hours after symptom
onset. ST2 levels higher than the respective gender-specific
upper reference levels were noted in 219 patients (44.8%) at
randomization, 140 patients (29.1%) at 24 hours, 104 pa-
tients (25.8%) at 48 hours, and 103 patients (25.6%) at
72 hours. Therefore, <1/2 of patients with NSTEMI have
ST2 levels above the normal range at presentation.
Supramedian admission ST2 levels (i.e., >28.4 ng/ml)
were associated with a higher percentage of men and more
hypertension but, in contrast to several earlier reports, no
greater prevalence of diabetes or renal dysfunction. Supra-
median ST2 also associated with significantly higher levels
of NT-proBNP, CRP, troponin, and CRP. There were sig-
nificant (p <0.01) albeit weak associations between ST2 and
cardiac troponin T (cTnT) (r ¼ 0.27), NT-proBNP (r ¼
0.25), CRP (r ¼ 0.15), and IL-6 (r ¼ 0.20) but not between
ST2 and eGFR (r ¼ 0.06, p ¼ 0.21).
Twenty-two patients (5.5%) died in the following year.
Randomization ST2 levels were higher in subsequent de-
cedents. Notably, this distinction was most clear cut at
randomization, and ST2 levels did not differ between groups
beyond 24 hours. This again emphasizes the importance of
early ST2 levels for the best prognostic information, a
pattern quite different from that of NT-proBNP. The AUC
of randomization ST2 levels for 1-year mortality was 0.67.
Corresponding and comparable AUCs for the other markers
were cTnT 0.64, CRP 0.69, IL-6 0.68, and eGFR 0.72.
Notably, NT-proBNP significantly (p ¼ 0.03) outperformed
ST2 and the other markers, with an AUC of 0.78. The
c-statistics for ST2 decreased progressively over serial
measurements down to 0.60 at 72 hours, implying the
importance of early ST2 measurement in the setting of ACS.
Multivariate analysis included clinical variables related
to 1-year mortality (age, HF, diabetes mellitus, previous MI,
and previous stroke). A 1-SD increase in log-transformed
ST2 was associated with an approximate twofold
increased risk (odds ratio 2.3, 95% CI 1.1 to 4.6, p ¼ 0.03).
However, adding other biomarkers to the model (cTnT, NT-
proBNP, CRP, IL-6, fibrinogen, and eGFR) removed the
independent prognostic value of initial ST2 levels. A 1-SD
increase in log NT-proBNP was the strongest risk predictor
(odds ratio 1.9, 95% CI 1.3 to 2.8, p ¼ 0.002). The shift in
ST2 levels from randomization to 72 hours was not pre-
dictive for 1-year mortality. Differences in sampling timesor the larger amount of affected myocardium in STEMI
compared with noneST-segment elevation ACS may both
be relevant. ST2 might be more useful for prognosis in
patients with larger MIs.
Dhillon et al11 examined both ST2 and IL-33 in NSTEMI
according to the same design as in their report on patients
with STEMI. Samples were acquired from 577 patients 3 to
5 days after admission. The primary end point was a com-
posite of major adverse cardiac events (MACEs; combined
mortality, HF admission, and reinfarction), with the indi-
vidual MACE components also analyzed as separate sec-
ondary end points. Increasing quartiles of ST2 were
associated with an increasing proportion of diabetes,
increased Killip class, and previous MI. ST2 was correlated
positively with NT-proBNP, GRACE risk score, glucose,
and age and negatively with eGFR (p <0.001 for all) but
was not related to troponin. Over an average follow-up
period of 532 days (range 150 to 1,059), 156 patients
(27%) had MACEs. ST2 was higher in these patients than in
event-free survivors (median 0.782 vs 0.596 ng/ml,
p <0.001). IL-33 levels did not differ for any end point. By
survival-curve analysis, mortality increased with increasing
quartile of ST2, but notably, separation by quartiles of
GRACE score for MACEs and death gave wider risk
stratification (with sharper separation of very high from very
low risk patients) than did ST2.
On multivariate analysis (with adjustment for age, gender,
previous angina or AMI, HF, hypertension, diabetes, Killip
class, eGFR, glucose, b blockers or statins, TnI, dyslipidemia,
and smoking), a 10-fold increase in ST2 was independently
associated with increased risk for MACEs (HR 2.01, p ¼
0.005), death, and MI during the long term. ST2 also inde-
pendently predicted 30-day mortality (HR 4.43, p ¼ 0.02,
c-statistic 0.73, p <0.001) and reinfarction (HR 2.48, p ¼
0.03). ST2 predicted HF in the short and long terms on uni-
variate analysis, but this relation was not seen in any multi-
variate model. The relation to long-term events remained on
further adjustment for GRACE risk score or for NT-proBNP
but not when the 2 were added to the model. Accordingly,
adding ST2 to GRACE risk score or to NT-proBNP did not
lead to improvements in the c-statistic for MACEs for long-
term follow-up or to significant net reclassification improve-
ment. Neither IL-33 nor its ratio with ST2 was prognostic.
The predictive signal from elevated ST2 for reinfarction
in this study is in jarring contrast to data from multiple
studies in patients with STEMI in which ST2 exhibited an
inverse relation to risk for further infarction.6e8 This
discrepancy is not readily explained.
The largest study of ST2 in noneST elevation ACS re-
ported to date is from the Metabolic Efficiency With
Ranolazine for Less Ischemia in the NoneST-Elevation
Acute Coronary SyndromeeTIMI 36 (MERLINeTIMI 36)
study, a placebo-controlled trial of ranolazine in noneST-
segment elevation ACS.12
Enrollees had some high-risk features, including
increased biomarkers, ST depression >0.1 mV, diabetes, or
Figure 2. Kaplan-Meier event rates for CV death or HF (A,B) and CVD (C) and HF (D) alone are highest in patients with high ST2 and high BNP.12
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in baseline samples from 4,426 of the 6,560 MER-
LINeTIMI 36 participants using the Presage ST2 method.
Median plasma ST2 was 24.4 ng/ml (IQR 17.6 to 35.1,
range 0.35 to 784.35). ST2 concentrations in the top quartile
(>35 ng/ml) were associated with greater age, a higher per-
centage of men, diabetes, and renal dysfunction but not with
any difference in the prevalence of antecedent MI or HF. ST2
was weakly correlated with troponin and BNP. High ST2 was
associated with increased risk for CVdeath or HF at 30 days
(6.6% vs 1.6%, p <0.0001) and 1 year (12.2% vs 5.2%, p
<0.0001). The risk associated with ST2 was significant after
adjustment for clinical covariates and biomarkers (including
age, coronary artery disease [CAD], diabetes, hypertension,
dyslipidemia, severe angina [>2 episodes in 24 hours], ST
changes >0.5 mm, aspirin, smoking, history of HF, eGFR
<60 ml/min, and other biomarkers, including cTnI, BNP,
myeloperoxidase, and high-sensitivity CRP). The LVEF was
added to the model when available.
The HR for CV death or HF at 30 days for ST2 >35
versus <35 ng/ml was 1.90 (95% CI 1.15 to 3.13, p ¼
0.012) and at 1 year was 1.51 (95% CI 1.15 to 1.98, p
<0.003), with significant integrated discrimination
improvement (p <0.0001) but no significant change in
c-statistic or net reclassification. Similar significant
increased risks (i.e., 1.5- to 2-fold) were also observed in
high-ST2 patients (i.e., >35 ng/ml) after completely
adjusted analyses for the 3 individual end points (i.e., all-
cause mortality, CV death, and HF). Unlike BNP, ST2
was not associated with the composite of CV death, MI, or
recurrent ischemia (HR 1.13, 95% CI 0.98 to 1.30, p ¼
0.10). This report did not include information on associa-
tions of ST2 with risk for reinfarction alone.
Again, combining ST2 with BNP improved risk stratifi-
cation. Event rates incurred by those with elevation of the2 markers were three- to fourfold those seen with low values
of the 2 markers (Figure 2).
Hence, in this very large (and therefore well-powered)
sample of moderate- to high-risk patients with noneST
elevation ACS, plasma ST2 proved predictive of death, CV
death, HF, and the composite of CV death and HF in the
short and long terms, independent of a comprehensive array
of clinical predictors and even when BNP and troponin
levels were also included in multivariate analyses.
A recent study has considered the predictive utility of
ST2 in a mixed population, not previously studied, with the
aim of comparing ST2 and IL-33 concentrations in patients
with stable angina (SA) and ACS and subjects without
CAD.13 Blood samples were taken from 373 consecutive
patients with angiographically proved CAD, including 178
with SA, 97 with NSTEMI, and 98 with STEMI. Control
subjects were 65 subjects without coronary stenosis on
coronary angiography.
ST2 levels were similar in controls (median 0.163 ng/ml,
IQR 0.114 to 0.260) and patients with SA (0.169 ng/ml,
IQR 0.079 to 0.260) (p ¼ 0.34). Levels were highest in
patients with STEMI (0.453 ng/ml, IQR 0.313 to 0.688)
compared with those with NSTEMI (0.269 ng/ml, IQR
0.157 to 0.496), those with SA, and controls. ST2 levels
were not associated with CV risk factors such as age,
gender, hypertension, family history of CAD, smoking,
hyperlipidemia, or diabetes but were correlated positively
with creatinine levels. IL-33 was detectable in 58.5%,
42.4%, 46.8%, and 43.6% of subjects without CAD and
patients with SA, NSTEMI, and STEMI, respectively, and
serum levels did not differ between groups.
Over a mean follow-up period of 43 months, 37 patients
(10%) died, and the combined end point (death, MI, and
readmission for cardiac cause) occurred in 66 patients
(17.6%). ST2 was higher in those who died than in survivors
Figure 3. Risk ratios of all-cause mortality (A) and CV mortality (B) in patients with stable CAD for ST2 in addition to NT-proBNP and high-sensitivity cTnT.
ST2 quartiles: Q1 <15.6 ng/ml, Q2 15.6 to 19.3 ng/ml, Q3 >19.3 to 24.6 ng/ml, Q4 >24.6 ng/ml; NT-proBNP quartiles: Q1 <113 ng/L, Q2 113 to 294 ng/L,
Q3 >294 to 874 ng/L, Q4 >874 ng/L; high-sensitivity cTNT quartiles: Q1 <6 ng/L, Q2 6 to 10 ng/L, Q3 >10 to 19 ng/L, Q4 >19 ng/L.15
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0.129 to 0.426], p <0.05). The highest quintile of soluble
ST2 serum levels significantly predicted mortality in the
total cohort. When the cohort was stratified according to
clinical presentation, ST2 was a strong predictor of mortality
in patients with STEMI (p <0.001) but not in those with
NSTEMI or SA. ST2 serum levels significantly predicted
the occurrence of the combined end point in patients with
STEMI (p <0.005) and patients with SA (p <0.05) but not
in those with NSTEMI. Multivariate analysis for the popu-
lation overall (adjusted for age, gender, hyperlipidemia,
hypertension, smoking, body mass index, and serum creat-
inine) indicated that the top quintile of ST2 serum levels was
an independent predictor of mortality (HR 2.2, 95% CI 1.1
to 4.4, p ¼ 0.03). This study indicates a gradient in circu-
lating ST2 from control and SA (which do not differ) to
NSTEMI patients, with the highest levels found in those
with STEMI. In this mixed population with a relatively
small sample size, ST2 was related to death and combined
end points over prolonged follow-up. These associations
were strongest for STEMI.ST2 in Stable Coronary Artery Disease
Our understanding of ST2 in chronic stable coronary disease
has been advanced by observations in a sizable cohort of
patients who underwent long-term follow-up in the Lud-
wigshafen Risk and Cardiovascular Health Study.14,15Dieplinger et al15 measured plasma ST2 plasma in 1,345
patients with stable CAD referred for coronary angiography
at a single center. The study group included 1,008 men
(75%) and 337 women (25%), with a median age of
65 years. Two hundred twenty-nine (17%) had 1 stenosis
between 20% and 49%, and 323 (24%) had 1-vessel, 300
(22%) 2-vessel, and 493 (37%) 3-vessel disease. As ex-
pected, CV risk factors and CV medication were highly
prevalent. The cohort included 129 patients with HF,
including 60 (47%) in New York Heart Association func-
tional class II, 59 (46%) in class III, and 10 (7.8%) in class
IV.
ST2 was not correlated with the angiographic severity of
CAD (r ¼ 0.038, p ¼ 0.159).
The primary end point was all-cause mortality. During a
median follow-up time of 9.8 years, 477 patients (36%)
died. The median ST2 plasma concentration at baseline was
significantly higher in subsequent decedents than in survi-
vors (21.4 vs 18.5 ng/ml, p <0.001). The third-quartile
value of ST2 was 24.6 ng/ml. In univariate analysis, ST2
in patients with ST2 >24.6 ng/ml had a twofold increased
risk for death, with risk ratios of 2.01 (95% CI 1.74 to 2.53,
p <0.001) for all-cause mortality and 2.19 (95% CI 1.73 to
2.76, p <0.001) for CV mortality, subsequently attenuated
but remaining significant on multivariate analysis (1.39 [9%
CI 1.10 to 1.76, p <0.006] for all-cause mortality and 1.44
[95% CI 1.08 to 1.93, p ¼ 0.013] for CV death) after
adjustment for clinical variables (gender, age, body mass
index, hypertension, dyslipidemia, diabetes, smoking status,
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disease, heart rate, the LVEF, and eGFR) and biomarkers
(high-sensitivity CRP, IL-6, NT-proBNP, high-sensitivity
cTnT, and Galectin-3).
Receiver-operating characteristic curve analyses for ST2
and mortality at 2 years (n ¼ 108 [8%]), 5 years (242
[18%]), and 9.8 years (477 [36%]) gave the highest AUC at
2 years (0.69), reducing to 0.64 at 5 years and lowest after
9.8 years at 0.61. In multivariate Cox proportional-hazards
regression analysis, ST2 was an independent predictor of
all-cause mortality (risk ratio per 1-SD increase in log-
transformed values 1.16, 95% CI 1.05 to 1.29, p <0.004).
In the same multivariate analysis, NT-proBNP and high-
sensitivity cTnT were also independent predictors,
whereas galectin-3 was not. ST2 in the highest quartile
(>24.6 ng/ml) was associated with a twofold increased risk
for death in univariate analysis that remained significant in
the adjusted model (1.39, 95% CI 1.10 to 1.76, p <0.006).
Hence, ST2 generally within the normal range (third-
quartile value of 24.6 vs about 35 ng/ml in the early post-MI
setting) had prognostic impact additive to NT-proBNP and
high-sensitivity cTnT, suggesting possible value from a
multimarker approach. Accordingly, risk was highest in
patients in the highest quartiles of ST2 and NT-proBNP, as
well in the highest quartiles of both ST2 and high-sensitivity
cTnT for all-cause and CV mortality (Figure 3).ST2 and Left Ventricular Remodeling in Ischemic Heart
Disease
Data relating circulating ST2 to cardiac structure and
function are relatively sparse and variable, with a number of
reports documenting a weak inverse relation between ST2
and the LVEF in varied CV disease cohorts.
Weir et al16 inspected this issue in depth, seeking to
assess the relation between ST2 and serial change in LV
function after AMI. ST2 levels were measured at baseline
and at 12 and 24 weeks in 100 patients (mean age
58.9  12.0 years, 77% men) admitted with AMI with
resultant LV systolic dysfunction. Patients underwent car-
diac magnetic resonance imaging and measurement of
NT-proBNP, norepinephrine, and aldosterone at each time
point. Median ST2 decreased from 0.2633 ng/ml at baseline
to 0.1400 ng/ml at 24 weeks (p <0.001). ST2 was correlated
significantly and inversely with the LVEF at baseline
(r ¼ 0.30, p <0.002) and 24 weeks (r ¼ 0.23, p ¼
0.026); change in ST2 was correlated with change in LV
end-diastolic volume index (r ¼ 0.24, p <0.023). These
correlations were of modest strength only and consistent
with previous reports. ST2 was positively associated with
infarct volume index at baseline (r ¼ 0.26, p <0.005) and at
24 weeks (r ¼ 0.22, p <0.037) and with change in infarct
volume index (r ¼ 0.28, p <0.001). Higher ST2 was
associated with greater infarct transmurality and endocardial
extent and the presence of microvascular obstruction. ST2was correlated significantly with norepinephrine and aldo-
sterone but not with NT-proBNP.
ST2 levels early after AMI are related to medium-term
changes in LV structure and function. Early postinfarction
ST2 is related to infarct size and LV remodeling and may be
of pathophysiologic importance in these processes.Future Perspectives and Unanswered Questions
It remains unclear what the appropriate ST2 upper reference
limit for predicting risk in patients with suspected or proved
ACS would be; data from MERLINeTIMI 36 suggest that
the conventional value of 35 ng/ml might be acceptable, but
whether gender-based thresholds might be considered is not
conclusively known. The timing of sampling requires
further clarity. To the extent that studies repeatedly show
superiority of earlier ST2 measures implies that in contrast
to data for NT-proBNP (for which values later in hospital-
ization provide superior prognostic information to baseline
in the setting of AMI), earlier measures for ST2 appear most
important.Summary
Circulating ST2 is related to risk for all-cause and CV death
and to HF in patients with undifferentiated chest pain as well
as in those with confirmed IHD, including STEMI,
NSTEMI, and chronic stable CAD. Although generally
higher in older patients and in those with diabetes, it is far
less obviously correlated with many traditional CV risk
factors (such as previous MI or HF, a poor LVEF,
hypertension, and reduced eGFR) than NT-proBNP or high-
sensitivity troponin T, presumably reflecting distinct path-
ways for stimulus and secretion.
ST2 has little diagnostic utility in chest pain, but it is
independently prognostic across the spectrum of IHD. This
is most reliably observed in STEMI and in large cohorts
followed for long periods. Early postinfarction ST2 levels
have the greatest prognostic power, and samples for this
purpose should be acquired as early as possible after pre-
sentation, as most of the prognostic signal is lost >24 hours
the onset of symptoms. Most of the risk conferred by ST2
levels is confined to those with plasma ST2 in the top
quartile. About half of patients with MI exhibit early post-
infarction ST2 greater than the normal range, and in those
with values in the top quartile (generally higher than about
35 ng/ml), risk for short- and long-term CV death and HF is
doubled after adjustment for clinical factors and for other
biomarkers. In stable patients with chronic IHD, the third-
quartile value is about 25 ng/ml, and risk ratios for those
with ST2 higher than this cut point are similar to those
observed for a cut point of about 35 ng/ml in ACS settings
(albeit with lower absolute event rates). There is consistent
and striking improvement in risk stratification when ST2
and BNP are combined. Whether routine measurement of
58B The American Journal of Cardiology (www.AJConline.org) Vol 115 (7S) April 2, 2015ST2 either alone or as part of a multimarker strategy can
facilitate improved management and outcomes in IHD
remains unknown and requires further investigation.Author Disclosures
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